Activity of myosin-II and MAPK is further enhanced in Src cells when they are surrounded by normal cells. (A,C) Immunofluorescence images of XZ sections of Src cells (stained with CMFDA, green) surrounded by Src cells (left panels) or by normal MDCK cells (right panels). Cells were stained with Hoechst 33342 (blue) and anti-MLC-P (p-MLC) antibody (A, red) or anti-MAPK-P (p-MAPK) antibody (C, red). Scale bars; 10 μm. (B,D) Quantification of immunofluorescence of MLC-P (B) or MAPK-P (D). Data are mean ± s.d. (B) *P<4×10−7, **P<6×10−15; n=38, 37 and 33 cells from three independent experiments. (D) *P<5×10−16, **P<3×10−11; n=45, 42 and 23 cells from three independent experiments. (E,F) Quantification of immunofluorescence of MLC-P (E) or MAPK-P (F) in Src cells that were cultured with normal MDCK cells in the presence of the indicated inhibitors. It should be noted that Blebbistatin suppresses ATPase activity of myosin-II without affecting the phosphorylation of MLC, thus the effect of Blebbistatin on MLC-P was not examined. Data are mean ± s.d. (E) n=80 and 62 cells from four independent experiments. (F) *P<0.0001, Z=4.2; **P<0.0001, Z=5.4; n=51, 28 and 40 cells from three independent experiments. Values are expressed as a ratio relative to Src cells alone (B,D) or to control (E,F). Two-tailed Student's t tests were used to determine P-values, except for Fig. 5F where Mann-Whitney U-tests were used.